We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+1.08%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$335M
AUM Growth
+$128M
Cap. Flow
+$125M
Cap. Flow %
37.46%
Top 10 Hldgs %
47.51%
Holding
207
New
53
Increased
79
Reduced
42
Closed
32
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HE icon
101
Hawaiian Electric Industries
HE
$2.33B
$365K 0.11%
+11,050
New +$337K
VNQ icon
102
Vanguard Real Estate ETF
VNQ
$39.9B
$361K 0.11%
4,373
-9,618
-69% -$783K
AGR
103
DELISTED
Avangrid, Inc.
AGR
$352K 0.11%
+9,298
New +$355K
CQP icon
104
Cheniere Energy
CQP
$31.8B
$340K 0.1%
11,804
-5,783
-33% -$164K
SGYP
105
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$336K 0.1%
55,250
-13,004
-19% -$68K
NS
106
DELISTED
NuStar Energy L.P.
NS
$332K 0.1%
6,673
+2,065
+45% +$98.4K
NJR icon
107
New Jersey Resources
NJR
$6.06B
$316K 0.09%
+8,900
New +$302K
CLVS
108
DELISTED
Clovis Oncology, Inc.
CLVS
$313K 0.09%
7,054
-10,811
-61% -$381K
PTLA
109
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$312K 0.09%
13,895
+4,160
+43% +$81.3K
LOXO
110
DELISTED
Loxo Oncology, Inc
LOXO
$302K 0.09%
9,411
-820
-8% -$21K
OKE icon
111
Oneok
OKE
$58.7B
$297K 0.09%
5,181
+1,590
+44% +$83.4K
KA
112
DELISTED
Kineta, Inc. Common Stock
KA
$296K 0.09%
+173
New +$282K
BCRX icon
113
BioCryst Pharmaceuticals
BCRX
$2.37B
$291K 0.09%
46,010
-38,897
-46% -$202K
PRTK
114
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$281K 0.08%
+18,271
New +$237K
MCRB icon
115
Seres Therapeutics
MCRB
$48.1M
$279K 0.08%
1,407
+1,002
+247% +$219K
SEP
116
DELISTED
Spectra Engy Parters Lp
SEP
$278K 0.08%
6,075
+1,870
+44% +$81.3K
EPZM
117
DELISTED
Epizyme, Inc
EPZM
$277K 0.08%
22,900
+1,150
+5% +$12K
CYTK icon
118
Cytokinetics
CYTK
$11B
$273K 0.08%
22,494
-6,885
-23% -$73.1K
TVRD
119
Tvardi Therapeutics
TVRD
$23.5M
$272K 0.08%
+814
New +$261K
BPMC
120
DELISTED
Blueprint Medicines
BPMC
$271K 0.08%
9,665
-3,381
-26% -$102K
NGNE icon
121
Neurogene
NGNE
$696M
$270K 0.08%
+817
New +$220K
XNCR icon
122
Xencor
XNCR
$1.44B
$270K 0.08%
10,262
-7,387
-42% -$178K
SAGE
123
DELISTED
Sage Therapeutics
SAGE
$269K 0.08%
5,277
-3,497
-40% -$165K
JUNO
124
DELISTED
Juno Therapeutics, Inc.
JUNO
$267K 0.08%
14,153
+8,136
+135% +$199K
KYNB
125
Kyntra Bio
KYNB
$28.5M
$266K 0.08%
497
-98
-16% -$48.9K

Similar funds

Virtus ETF Advisers's Q4 2016 Portfolio in Review

As of Q4 2016, Virtus ETF Advisers held 207 positions worth $335M, up 62% from $207M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Virtus ETF Advisers deployed $125M of net new capital in Q4 2016, opening 53 new positions and adding to 79 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 107,222 shares worth $24M.

By sector, the portfolio is most concentrated in Energy at 57% of assets, down from 64% a quarter earlier, followed by Healthcare and Utilities.

On the sell side, the largest reduction was Williams Companies, an estimated $1.69M trimmed.

  • Virtus ETF Advisers's largest Q4 2016 buy was State Street SPDR S&P 500 ETF Trust: 107,222 shares worth $24M.
  • Virtus ETF Advisers added most to Energy Transfer Partners L.p. in Q4 2016, an estimated $7.84M increase.
  • Virtus ETF Advisers's biggest Q4 2016 reduction was Williams Companies, cutting an estimated $1.69M.
  • Virtus ETF Advisers fully exited iShares 20+ Year Treasury Bond ETF in Q4 2016, selling an estimated $1.69M.
  • Virtus ETF Advisers's ten largest holdings make up 48% of its $335M portfolio in Q4 2016.
  • Virtus ETF Advisers opened 53 new positions and closed 32 in Q4 2016.
  • Virtus ETF Advisers's portfolio value rose 62% quarter-over-quarter to $335M.

Based on Virtus ETF Advisers's 13F filing for Q4 2016, filed 14 Feb 2017.